Drug intelligence / Profile preview

AVS1002

Development stage: Unknown
Lead developer: Avelos Therapeutics
Modality: Small Molecules
Administration: Unknown

Overview

AVS1002 is a small molecule being developed by Avelos Therapeutics as a DNA damage modulator for the treatment of cancer. It is particularly aimed at patients with homologous recombination deficiency (HRD) in the DNA damage response, which could provide an alternative for those resistant to PARP inhibitors.

Other names: AVS-1002AVS1002AVS 1002

Beyond the preview

Go deeper on AVS1002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AVS1002.

Explore the full profile